Literature DB >> 22262068

Physiology of incretins in health and disease.

Carolyn F Deacon1, Bo Ahrén.   

Abstract

The incretin hormones, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), are gut peptides which are secreted by endocrine cells in the intestinal mucosa. Their plasma concentrations increase quickly following food ingestion, and carbohydrate, fat, and protein have all been shown to stimulate GLP-1 and GIP secretion. Although neural and hormonal mechanisms have also been proposed to regulate incretin hormone secretion, direct stimulation of the enteroendocrine cells by the presence of nutrients in the intestinal lumen is probably the most important factor in humans. The actions of the incretin hormones are crucial for maintaining normal islet function and glucose homeostasis. Furthermore, it is also now being recognized that incretin hormones may have other actions in addition to their glucoregulatory effects. Studies have shown that GLP-1 and GIP levels and actions may be perturbed in disease states, but interpretation of the precise relationship between disease and incretins is difficult. The balance of evidence seems to suggest that alterations in secretion and/or action of incretin hormones arise secondarily to the development of insulin resistance, glucose intolerance, and/or increases in body weight rather than being causative factors. However, these impairments may contribute to the deterioration of glycemic control in diabetic patients.
Copyright © by Lab & Life Press/SBDR

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22262068      PMCID: PMC3280665          DOI: 10.1900/RDS.2011.8.293

Source DB:  PubMed          Journal:  Rev Diabet Stud        ISSN: 1613-6071


  127 in total

1.  Release of glucagon-like peptide 1 (GLP-1 [7-36 amide]), gastric inhibitory polypeptide (GIP) and insulin in response to oral glucose after upper and lower intestinal resections.

Authors:  M A Nauck; J Siemsglüss; C Orskov; J J Holst
Journal:  Z Gastroenterol       Date:  1996-03       Impact factor: 2.000

Review 2.  Incretin hormone secretion over the day.

Authors:  Bo Ahrén; Richard D Carr; Carolyn F Deacon
Journal:  Vitam Horm       Date:  2010       Impact factor: 3.421

3.  Dipeptidyl peptidase-4 inhibitors administered in combination with metformin result in an additive increase in the plasma concentration of active GLP-1.

Authors:  E M Migoya; R Bergeron; J L Miller; R N K Snyder; M Tanen; D Hilliard; B Weiss; P Larson; M Gutierrez; G Jiang; F Liu; K A Pryor; J Yao; L Zhu; J J Holst; C Deacon; G Herman; N Thornberry; J Amatruda; D Williams-Herman; J A Wagner; R SinhaRoy
Journal:  Clin Pharmacol Ther       Date:  2010-11-03       Impact factor: 6.875

4.  Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects.

Authors:  C F Deacon; M A Nauck; M Toft-Nielsen; L Pridal; B Willms; J J Holst
Journal:  Diabetes       Date:  1995-09       Impact factor: 9.461

5.  GLP-1 antagonism with exendin (9-39) fails to increase spontaneous meal size in rats.

Authors:  Elisabeth B Rüttimann; Myrtha Arnold; Nori Geary; Wolfgang Langhans
Journal:  Physiol Behav       Date:  2010-03-03

6.  Reduced glucose tolerance and insulin resistance induced by steroid treatment, relative physical inactivity, and high-calorie diet impairs the incretin effect in healthy subjects.

Authors:  K B Hansen; T Vilsbøll; J I Bagger; J J Holst; F K Knop
Journal:  J Clin Endocrinol Metab       Date:  2010-04-21       Impact factor: 5.958

7.  The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action.

Authors:  Kristine J Hare; Tina Vilsbøll; Meena Asmar; Carolyn F Deacon; Filip K Knop; Jens J Holst
Journal:  Diabetes       Date:  2010-02-11       Impact factor: 9.461

8.  Expression and functional activity of glucagon, glucagon-like peptide I, and glucose-dependent insulinotropic peptide receptors in rat pancreatic islet cells.

Authors:  K Moens; H Heimberg; D Flamez; P Huypens; E Quartier; Z Ling; D Pipeleers; S Gremlich; B Thorens; F Schuit
Journal:  Diabetes       Date:  1996-02       Impact factor: 9.461

9.  Intra-islet regulation of hormone secretion by glucagon-like peptide-1-(7--36) amide.

Authors:  R S Heller; G W Aponte
Journal:  Am J Physiol       Date:  1995-12

10.  Gastric emptying and release of incretin hormones after glucose ingestion in humans.

Authors:  J Schirra; M Katschinski; C Weidmann; T Schäfer; U Wank; R Arnold; B Göke
Journal:  J Clin Invest       Date:  1996-01-01       Impact factor: 14.808

View more
  31 in total

Review 1.  The continuing need for drug development and clinical trials in type 2 diabetes and its complications: introduction to the RDS special issue.

Authors:  Itamar Raz; Baptist Gallwitz
Journal:  Rev Diabet Stud       Date:  2011-11-10

2.  Monomethylated-adenines potentiate glucose-induced insulin production and secretion via inhibition of phosphodiesterase activity in rat pancreatic islets.

Authors:  Brandon B Boland; Cristina Alarcón; Almas Ali; Christopher J Rhodes
Journal:  Islets       Date:  2015-09-24       Impact factor: 2.694

3.  Why is it so difficult to measure glucagon-like peptide-1 in a mouse?

Authors:  Johanne A Windeløv; Nicolai J Wewer Albrechtsen; Rune E Kuhre; Sara L Jepsen; Daniel Hornburg; Jens Pedersen; Elisa P Jensen; Katrine D Galsgaard; Marie Winther-Sørensen; Anne Ørgaard; Carolyn F Deacon; Matthias Mann; Hannelouise Kissow; Bolette Hartmann; Jens J Holst
Journal:  Diabetologia       Date:  2017-07-01       Impact factor: 10.122

Review 4.  The alpha-cell as target for type 2 diabetes therapy.

Authors:  Mikkel Christensen; Jonatan I Bagger; Tina Vilsbøll; Filip K Knop
Journal:  Rev Diabet Stud       Date:  2011-11-10

5.  Acute and short-term effects of caloric restriction on metabolic profile and brain activation in obese, postmenopausal women.

Authors:  S Jakobsdottir; I C van Nieuwpoort; C C van Bunderen; M B de Ruiter; J W R Twisk; J B Deijen; D J Veltman; M L Drent
Journal:  Int J Obes (Lond)       Date:  2016-05-24       Impact factor: 5.095

Review 6.  Ghrelin, CCK, GLP-1, and PYY(3-36): Secretory Controls and Physiological Roles in Eating and Glycemia in Health, Obesity, and After RYGB.

Authors:  Robert E Steinert; Christine Feinle-Bisset; Lori Asarian; Michael Horowitz; Christoph Beglinger; Nori Geary
Journal:  Physiol Rev       Date:  2017-01       Impact factor: 37.312

7.  Effects of small intestinal glucose on glycaemia, insulinaemia and incretin hormone release are load-dependent in obese subjects.

Authors:  L G Trahair; C S Marathe; S Standfield; C K Rayner; C Feinle-Bisset; M Horowitz; K L Jones
Journal:  Int J Obes (Lond)       Date:  2016-12-06       Impact factor: 5.095

Review 8.  Sodium glucose cotransporter SGLT1 as a therapeutic target in diabetes mellitus.

Authors:  Panai Song; Akira Onishi; Hermann Koepsell; Volker Vallon
Journal:  Expert Opin Ther Targets       Date:  2016-04-12       Impact factor: 6.902

Review 9.  Drugs or diet?--Developing novel therapeutic strategies targeting the free fatty acid family of GPCRs.

Authors:  H J Dranse; M E M Kelly; B D Hudson
Journal:  Br J Pharmacol       Date:  2013-10       Impact factor: 8.739

10.  Short-term administration of the GLP-1 analog liraglutide decreases circulating leptin and increases GIP levels and these changes are associated with alterations in CNS responses to food cues: A randomized, placebo-controlled, crossover study.

Authors:  Olivia M Farr; Michael A Tsoukas; Georgios Triantafyllou; Fadime Dincer; Andreas Filippaios; Byung-Joon Ko; Christos S Mantzoros
Journal:  Metabolism       Date:  2016-03-18       Impact factor: 8.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.